Compare DexCom, Inc. (DXCM) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Rocket Lab USA Inc — how do they compare? DexCom, Inc. trades at $78.68 (market cap $28.06B), while Rocket Lab USA Inc trades at $68.32 (market cap $47.61B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | RKLB | |
|---|---|---|
Market Cap | $28.06B | $47.61B |
Sector | Health | Technology |
52-Week High | $89.53 | $150.23 |
52-Week Low | $54.84 | $39.48 |
Enterprise Value | $27.03B | $46.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Rocket Lab (RKLB) is trading at $68.94, down 12.52% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $601.8M in 2025 but remains unprofitable with a -26.87% net margin. Analyst sentiment remains positive with 75% buy ratings and a $115.82 price target, while recent news highlights contract wins and Neutron rocket development as key catalysts.
The stock presents high-risk growth potential with significant upside to analyst targets but faces execution risks on path to profitability. Key opportunities include defense contract potential and space infrastructure expansion, while losses and cash burn require careful monitoring. The current pullback offers entry for risk-tolerant investors betting on space sector growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
